Evidence map›Paper›PMID 38576607›Full record

ArticleFrontiers in immunology2024

Minerva Arce-Fonseca, Dulce Mata-Espinosa, Alberto Aranda-Fraustro, José Luis Rosales-Encina, Mario Alberto Flores-Valdez, Olivia Rodríguez-Morales

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
2.1field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Vaccination with aMicroorganisms · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Minerva Arce-FonsecaLaboratory of Molecular Immunology and Proteomics, Department of Molecular Biology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.
Dulce Mata-EspinosaLaboratory of Experimental Pathology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Alberto Aranda-FraustroDepartment of Pathology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.
José Luis Rosales-EncinaLaboratory of Molecular Biology, Department of Infectomics and Molecular Pathogenesis, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Mexico City, Mexico.
Mario Alberto Flores-ValdezBiotecnología Médica y Farmacéutica, Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco, A. C., Guadalajara, Mexico.
Olivia Rodríguez-MoralesLaboratory of Molecular Immunology and Proteomics, Department of Molecular Biology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.
Instituto Nacional de Cardiología · MXInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán · MXInstituto Politécnico Nacional · MXSecretaría de Salud de Jalisco · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: There is currently no vaccine against Chagas disease (ChD), and the medications available confer multiple side effects. Methods: BALB/c mice were immunized with BCG subcutaneously, and 60 days later, they were infected with Results: Vaccination reduced parasitemia by 70%, and 100% survival was achieved in the acute stage; although the presentation of clinical signs was reduced, there was no increase in the antibody titer or in the differential production of the isotypes. Conclusion: Serum cytokine production indicated a proinflammatory response in infected animals, while in those who received BCG, the response was balanced by inducing Th1/Th2-type cytokines, with a better prognosis of the disease in the chronic stage.

Indexed as

Chagas DiseaseMycobacterium bovisAdjuvants, ImmunologicAnimalsBCG VaccineMiceParasitemiaPersistent InfectionAdjuvants, ImmunologicBCG VaccineBCGChagas diseaseimmunomodulatortrained/nonspecific immunityTrypanosoma cruzivaccination

Identifiers

PMID38576607
PMCPMC10991741
OpenAlexW4393053177

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.